FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211897764> ?p ?o ?g. }

• W3211897764 endingPage "878" @default.
• W3211897764 startingPage "878" @default.
• W3211897764 abstract "Abstract Introduction: Clinical trials of novel salvage therapies (ST) have encouraging outcomes for relapsed/refractory classic Hodgkin lymphoma (R/R cHL) after autologous stem cell transplant (ASCT); yet studies comparing novel ST with conventional salvage chemotherapy are lacking. In a single center cohort, we demonstrated that bendamustine/brentuximab (BBV) had higher overall response rates (ORR) and complete response (CR) rates in ASCT-eligible R/R cHL (Desai et al JCO, 2021). Herein we report comparative outcomes of novel and conventional ST in R/R cHL who undergo ASCT, in a large multicenter retrospective cohort. Methods: Consecutive R/R cHL pts who underwent ASCT at 12 institutions across United States were included. Demographics and clinical variables at relapse including age, sex, B symptoms, stage, bulky disease (BD, single mass &gt; 6 cm) extra nodal disease (END), primary refractory disease (PRD) and early relapse (ER, within 1 year) were recorded by electronic health records review. Study objectives were ORR, CR to first ST, post-ASCT PFS and OS by final ST. Time to event endpoints were defined from date of ASCT. Results: From 12 participating institutions, 853 pts of R/R cHL who underwent ASCT were eligible for this study. Median age was 33 (14-72) years, 457 (54%) were male, 446 (52%) had BD, 257 (30%) had advanced stage, 271 (32%) had END, 369 (43%) had B symptoms, 142 (17%) had PRD and 307 (36%) had ER. All 853 received at least 1 ST, 245 received 2 ST, 71 received 3 ST and 26 received 4 ST. Seven groups of ST were identified: 1. Conventional platinum-based chemotherapy (PBC) group including ICE, DHAP and ESHAP 2. BBV 3. Brentuximab Vedotin and nivolumab (BV/Nivo) 4. BV alone (BV) 5. gemcitabine-based chemotherapy (Gem) 6. checkpoint inhibitors (CPI) and 7. other miscellaneous agents (Misc). 1st ST was as follows: 553 had PBC; 69 had BBV; 48 had BV/Nivo; 65 had BV; 49 had Gem; 4 had CPI and 63 had Misc. There was no significant difference in the baseline characteristics by type of 1 st ST (data not shown). BBV had significantly higher ORR (92% vs 79%, p&lt;0.001) and CR rate (80% vs 49%, p &lt;0.001) compared to PBC. BV/Nivo had significantly higher CR rate (67% vs 49%, p &lt;0.001) and a trend towards higher ORR (86% vs 79%, p = 0.1) compared to PBC. BV had significantly lower ORR (62% vs 79%, p &lt;0.001) and CR rate (34% vs 49%, p &lt;0.001) compared to PBC. There was no difference in ORR and CR rate of PBC, Gem, CPI and Misc agents. Final ST prior to ASCT was PBC in 451, BBV in 76, BV/Nivo in 48, BV in 87, CPI in 24, Gem in 90 and Misc in 64. Table 1 lists K-M estimates of 2-year survival probabilities for different Final ST groups. Median follow up was 3 (range 0.1-13) years. BV/Nivo group had significantly higher proportion of patients with PRD and BD than PBC, no other differences in baseline characteristics were identified amongst ST groups (data not shown). BV/Nivo (HR: 0.1 (CI 95:0.02-0.4), p&lt;0.01) and CPI (HR: 0.12 (CI 95:0.03-0.5), p&lt;0.01) had significantly higher PFS than PBC. There was no significant difference in PFS between other ST groups (Figure 1a). Type of ST was not significantly associated with difference in OS (Figure 1b). 536 pts underwent ASCT in CR, 273 underwent ASCT in partial response (PR) and 31 underwent ASCT with progressive disease (PD). Pre-ASCT PR (HR 1.6 (CI 95:1.3-2.6), p&lt;0.001) and PD (HR: 4.1 (CI 95: 2.5-6.8), p&lt;0.001) predicted significantly lower PFS compared to CR (Figure 2a). OS was also significantly lower in pts with pre-ASCT PR (HR 1.7 (CI 95: 1.2-1.6), p&lt;0.001) and PD (HR 5.3 (CI 95: 2.8-10), p&lt;0.001) (Figure 2b). Higher number of pre-ASCT ST predicted lower PFS (HR 1.3 (CI 95: 1.1-1.6), p&lt;0.001) and OS (HR 1.5 (CI 95: 1.2-1.8), p&lt;0.001). In pts with pre-ASCT CR, all 36 who had pre-ASCT CR after BV/Nivo were alive and relapse free for follow up of 0.1-5 yrs. BV/Nivo was associated with significantly higher PFS (HR 0.1 (CI 95: 0.01-0.7), p &lt;0.05) but not OS compared to PBC in this subgroup. Increasing number of pre-ASCT ST predicted worse PFS (HR 1.5 (CI 95: 1.2-2.0), p&lt;0.01) and OS (HR 2.2 (CI 95: 1.4-3.4), p&lt;0.001) in this subgroup as well. Conclusions: BV/Nivo has a higher CR rate and better post-ASCT PFS compared to conventional chemotherapy and can lead to durable remissions in pts with pre-ASCT CR. BBV had a higher response rate and similar post-ASCT survival to conventional chemotherapy. BV had lower response rates compared to chemotherapy. Novel ST such as BV/Nivo and BBV may be preferable to conventional chemotherapy in R/R cHL. Figure 1 Figure 1. Disclosures Spinner: Notable Labs: Honoraria. Bachanova: FATE: Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Research Funding; KaryoPharma: Membership on an entity's Board of Directors or advisory committees; Gamida Cell: Membership on an entity's Board of Directors or advisory committees, Research Funding. Dorritie: SITC presentation: Honoraria; Genmab: Research Funding; University of Pittsburgh/UPMC Hillman Cancer Center: Current Employment; Janssen: Research Funding; F. Hoffman-La Roche Ltd: Research Funding; Juno/BMS: Research Funding; Kite, a Gilead Company: Research Funding; OncLive/Institutional Perspectives on Cancer presentation: Honoraria. Arai: Magenta Therapeutics: Research Funding. Maurer: Nanostring: Research Funding; Morphosys: Membership on an entity's Board of Directors or advisory committees, Research Funding; Kite Pharma: Membership on an entity's Board of Directors or advisory committees; Genentech: Research Funding; Celgene: Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees. Diefenbach: Genentech, Inc./ F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Celgene: Research Funding; IMab: Research Funding; Morphosys: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding; Merck Sharp & Dohme: Consultancy, Honoraria, Research Funding; Perlmutter Cancer Center at NYU Langone Health: Current Employment; AbbVie: Research Funding; IGM Biosciences: Research Funding; Incyte: Research Funding; Trillium: Research Funding; Gilead: Current equity holder in publicly-traded company; MEI: Consultancy, Research Funding. Nowakowski: Kyte Pharma: Consultancy; Ryvu Therapeutics: Consultancy; Selvita: Consultancy; Curis: Consultancy; Karyopharm Therapeutics: Consultancy; Celgene/Bristol Myers Squibb: Consultancy, Research Funding; Roche: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; MorphoSys: Consultancy; Bantham Pharmaceutical: Consultancy; Daiichi Sankyo: Consultancy; Zai Labolatory: Consultancy; Incyte: Consultancy; Kymera Therapeutics: Consultancy; TG Therapeutics: Consultancy; Blueprint Medicines: Consultancy; Nanostrings: Research Funding. Advani: Astellas/Agensys: Research Funding; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Bayer: Membership on an entity's Board of Directors or advisory committees; Bristol Myer Squibb: Membership on an entity's Board of Directors or advisory committees; Cell Medica: Membership on an entity's Board of Directors or advisory committees; Forty Seven: Membership on an entity's Board of Directors or advisory committees, Research Funding; Genetech Inc.: Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Membership on an entity's Board of Directors or advisory committees; Janssen Pharmaceutical: Research Funding; Juno: Membership on an entity's Board of Directors or advisory committees; Kite Pharma: Membership on an entity's Board of Directors or advisory committees; Kura: Research Funding; Kyowa: Membership on an entity's Board of Directors or advisory committees; Merck: Research Funding; Millenium: Research Funding; Pharmacyclics: Consultancy, Research Funding; Portola Pharmaceuticals: Consultancy; Regeneron: Research Funding; Roche: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees." @default.
• W3211897764 created "2021-11-22" @default.
• W3211897764 creator A5004343197 @default.
• W3211897764 creator A5013911840 @default.
• W3211897764 creator A5014995908 @default.
• W3211897764 creator A5023347189 @default.
• W3211897764 creator A5024808138 @default.
• W3211897764 creator A5024909755 @default.
• W3211897764 creator A5025159353 @default.
• W3211897764 creator A5035919084 @default.
• W3211897764 creator A5036343829 @default.
• W3211897764 creator A5040662951 @default.
• W3211897764 creator A5041482839 @default.
• W3211897764 creator A5047509474 @default.
• W3211897764 creator A5047921040 @default.
• W3211897764 creator A5048644166 @default.
• W3211897764 creator A5051860285 @default.
• W3211897764 creator A5056210769 @default.
• W3211897764 creator A5060314041 @default.
• W3211897764 creator A5061713890 @default.
• W3211897764 creator A5067489954 @default.
• W3211897764 creator A5067743181 @default.
• W3211897764 creator A5069112595 @default.
• W3211897764 creator A5069163533 @default.
• W3211897764 creator A5081722870 @default.
• W3211897764 date "2021-11-05" @default.
• W3211897764 modified "2023-10-01" @default.
• W3211897764 title "Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant" @default.
• W3211897764 doi "https://doi.org/10.1182/blood-2021-149880" @default.
• W3211897764 hasPublicationYear "2021" @default.
• W3211897764 type Work @default.
• W3211897764 sameAs 3211897764 @default.
• W3211897764 citedByCount "2" @default.
• W3211897764 countsByYear W32118977642022 @default.
• W3211897764 countsByYear W32118977642023 @default.
• W3211897764 crossrefType "journal-article" @default.
• W3211897764 hasAuthorship W3211897764A5004343197 @default.
• W3211897764 hasAuthorship W3211897764A5013911840 @default.
• W3211897764 hasAuthorship W3211897764A5014995908 @default.
• W3211897764 hasAuthorship W3211897764A5023347189 @default.
• W3211897764 hasAuthorship W3211897764A5024808138 @default.
• W3211897764 hasAuthorship W3211897764A5024909755 @default.
• W3211897764 hasAuthorship W3211897764A5025159353 @default.
• W3211897764 hasAuthorship W3211897764A5035919084 @default.
• W3211897764 hasAuthorship W3211897764A5036343829 @default.
• W3211897764 hasAuthorship W3211897764A5040662951 @default.
• W3211897764 hasAuthorship W3211897764A5041482839 @default.
• W3211897764 hasAuthorship W3211897764A5047509474 @default.
• W3211897764 hasAuthorship W3211897764A5047921040 @default.
• W3211897764 hasAuthorship W3211897764A5048644166 @default.
• W3211897764 hasAuthorship W3211897764A5051860285 @default.
• W3211897764 hasAuthorship W3211897764A5056210769 @default.
• W3211897764 hasAuthorship W3211897764A5060314041 @default.
• W3211897764 hasAuthorship W3211897764A5061713890 @default.
• W3211897764 hasAuthorship W3211897764A5067489954 @default.
• W3211897764 hasAuthorship W3211897764A5067743181 @default.
• W3211897764 hasAuthorship W3211897764A5069112595 @default.
• W3211897764 hasAuthorship W3211897764A5069163533 @default.
• W3211897764 hasAuthorship W3211897764A5081722870 @default.
• W3211897764 hasBestOaLocation W32118977641 @default.
• W3211897764 hasConcept C126322002 @default.
• W3211897764 hasConcept C142424586 @default.
• W3211897764 hasConcept C143998085 @default.
• W3211897764 hasConcept C2776694085 @default.
• W3211897764 hasConcept C2779050716 @default.
• W3211897764 hasConcept C2779338263 @default.
• W3211897764 hasConcept C2780775027 @default.
• W3211897764 hasConcept C28328180 @default.
• W3211897764 hasConcept C2911091166 @default.
• W3211897764 hasConcept C502942594 @default.
• W3211897764 hasConcept C54355233 @default.
• W3211897764 hasConcept C71924100 @default.
• W3211897764 hasConcept C86803240 @default.
• W3211897764 hasConcept C87355193 @default.
• W3211897764 hasConceptScore W3211897764C126322002 @default.
• W3211897764 hasConceptScore W3211897764C142424586 @default.
• W3211897764 hasConceptScore W3211897764C143998085 @default.
• W3211897764 hasConceptScore W3211897764C2776694085 @default.
• W3211897764 hasConceptScore W3211897764C2779050716 @default.
• W3211897764 hasConceptScore W3211897764C2779338263 @default.
• W3211897764 hasConceptScore W3211897764C2780775027 @default.
• W3211897764 hasConceptScore W3211897764C28328180 @default.
• W3211897764 hasConceptScore W3211897764C2911091166 @default.
• W3211897764 hasConceptScore W3211897764C502942594 @default.
• W3211897764 hasConceptScore W3211897764C54355233 @default.
• W3211897764 hasConceptScore W3211897764C71924100 @default.
• W3211897764 hasConceptScore W3211897764C86803240 @default.
• W3211897764 hasConceptScore W3211897764C87355193 @default.
• W3211897764 hasIssue "Supplement 1" @default.
• W3211897764 hasLocation W32118977641 @default.
• W3211897764 hasOpenAccess W3211897764 @default.
• W3211897764 hasPrimaryLocation W32118977641 @default.
• W3211897764 hasRelatedWork W1818467446 @default.
• W3211897764 hasRelatedWork W1990308918 @default.
• W3211897764 hasRelatedWork W2021240435 @default.
• W3211897764 hasRelatedWork W2108711134 @default.
• W3211897764 hasRelatedWork W2174339712 @default.
• W3211897764 hasRelatedWork W2319149848 @default.

• next